Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor ContactTina Ventura, IR@madrigalpharma.com

Media ContactChristopher Frates, media@madrigalpharma.com

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
Von Sep 2024 bis Okt 2024 Click Here for more Madrigal Pharmaceuticals Charts.
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
Von Okt 2023 bis Okt 2024 Click Here for more Madrigal Pharmaceuticals Charts.